SynthesisClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
LncRNAs as Emerging Diagnostic Biomarkers for Cardiovascular Diseases: Evidence Synthesis Through Systematic Review and Meta-Analysis.
Synthesis in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundCardiovascular diseases (CVDs) are the leading cause of global morbidity and mortality. Long non-coding RNAs (lncRNAs) have emerged as potential diagnostic biomarkers for CVDs.AimTo systematically evaluate the diagnostic value of lncRNAs for CVDs through a systematic review and meta-analysis.MethodsStudies focusing on lncRNAs as diagnostic markers for CVDs were searched from PubMed, Embase, and Web of Science databases. The meta-analysis was conducted according to the PRISMA 2020 guidelines. The diagnostic value of lncRNAs was calculated by pooled sensitivity, specificity, and area under the summary receiver operating characteristic (SROC) curve (AUC). Meta-regression and subgroup analyses were performed to explore heterogeneity sources. Publication bias and sensitivity analysis were also conducted.ResultsA total of 16 articles (18 lncRNAs, 1125 controls, and 1855 cases) were included. LncRNAs showed pooled sensitivity of 0.81 (95% CI = 0.76-0.85) and specificity of 0.86 (95% CI = 0.80-0.90) for CVDs diagnosis. The SROC analysis revealed an AUC of 0.90 (95% CI = 0.87-0.92), indicating high diagnostic accuracy. The positive diagnostic likelihood ratio (DLR) was 5.73 (95% CI =4.07-8.08), and the negative DLR was 0.22 (95% CI = 0.18-0.28). The diagnostic score was 3.25 (95% CI = 2.79-3.71), the diagnostic odds ratio was 25.77 (95% CI = 16.22-40.93). The expression trend of lncRNAs, control type, and disease type were the main sources of heterogeneity.ConclusionLncRNAs had high sensitivity and specificity for CVDs diagnosis, showing great potential as auxiliary diagnostic tools.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.